Research Area
5-MER peptide (5-MP; Methionine Threonine, Alanine, Aspartic Acid, Valin) inhibits the pathology of animal models of chronic inflammations such as Rheumatoid Arthritis , Inflammatory Bowel Disease ,multiple Sclerosis as well as animal models of fibrosis, including systemic sclerosis, idiopathic pulmonary fibrosis (IPF) and severe lung fibrotic damage in COVID-19 infection. The peptide was derived from a sequence of 5 amino acids of pro-inflammatory CD44 variant , that involved in the pathology of this protein (J. Clin. Invest. 111, 1211-1220, 2003). The peptide targets and neutralizes Serum Amyloid A (SAA), which fuels the release of pro-inflammatory cytokine (IL-6, IL-1 beta and TNFalfa) from activated fibroblasts and monocytes , resulting with inflammatory damage to the body tissue (J Autoimmun . 2021 Nov; 124:102713). Further, the peptide activates genes , which protect against chronic inflammation and neurodegeneration. However, the peptide does not interfere with normal immune responses, such anti-infection antibodies stressing its specificity . 5-MP suppresses cytokine release of pro-inflammatory cytokines and proliferation of fibroblasts and monocytes involved in chronic inflammation and fibrosis . These findings suggest that 5-MP could be a promising drug for chronic inflammation and fibrosis-associated diseases, displaying an unmet therapeutic needs. Indeed, the 5-MP showed lack of toxicity in phase-1 clinical trial. For these research achievements professor Naor received the prestige 2021 kaye prize of the Hebrew University of Jerusalem for scientific innovation .
Team Description
Dr Hassan Elsana, a post doc , exploring the effect of 5-MP on Amyloid beta of Alzheimer disease showing encouraging results. Dr. Rawan Atiq,a post doc, exploring the targeting mechasnism of 5-MP Dr Toshiyuki Murai, a Japanese collaborator on the effect of 5-MP on Amyloid beta. Dr. Maayan Hemed Shaked , a post doc , exploring the effect of 5-MP on chronic inflammation. Dr Keren-Or Amar, a postdoc . exploring the the effect of 5-MP rheumatoid Arthritis Dr Shmuel Cohen, a collaborator , Co-principle investigator.
Team Members
Team Show
Publications
PUBLICATION LIST
1. A. Shulov and D. Naor. Experiments on the olfactory responses and host-specificity of the oriental rat flea (Xenopsylla Cheopis). Parasitology 54:225-231, 1964.
2. M. Ickowicz, A. Shulov and D. Naor. The effect of Vipera Palestina venom on the thymus and lymph nodes. Harefuah 70:265-266, 1966.
3. M. Ickowicz, A. Shulov and D. Naor. The effect of Vipera Palestina venom on the thymus, lymph nodes and kidneys. Toxicon 3:305-306, 1966.
4. D. Naor and D. Sulitzeanu. Binding of radioiodinated bovine serum albumin to mouse spleen cells. Nature 214:687-688, 1967.
5. D. Naor and D. Sulitzeanu. Binding of radioiodinated bovine serum albumin to lymphoid cells specifically primed or immunized mice in vitro. Life Sciences. 7:(2),377-382, 1969.
6. D. Naor and D. Sulitzeanu. Affinity of radioiodinated bovine serum albumin for lymphoid cells. Binding of I125BSA to lymphoid cells of immune mice. Israel J. Med. Sci. 5:217-229, 1969.
7. D. Sulitzeanu and D. Naor. The affinity of radioiodinated BSA for lymphoid cells.Binding of 125I-BSA to lymphoid cells of normal mice. Int. Arch. Allergy Appl. Immunol.35:564-578, 1969.
8. Naor, Z. Bentwich and G. Cividalli. Inability of peripheral lymphoid cells of agammaglobulinaemic patients to bind radioiodinated albumins. Aust. J. Exp. Biol.Med. Sci. 47:(6) 759-761, 1969.
9. D. Naor and D. Sulitzeanu. Binding of 125I-BSA to lymphoid cells of tolerant mice.Int. Arch. Allergy Appl. Immunol. 36:112-113, 1969.
10. D. Naor. Antigen uptake by lymphoid cells of normal, immune and tolerant mice.Ph.D. thesis, 1968.
11. D. Naor and D. Sulitzeanu. The affinity of radioiodinated bovine serum albumin for lymphoid cells. II. Further experiments with cells of normal animals. Israel J. Med. Sci.6:519-522, 1970.
12. D. Naor, R.I. Mishell and L. Wofsy. Specific inhibition of an anti-hapten immune response by chemical modification of cells. Immunol. 105:1322-1326, 1970.
13. Wofsy, P. Truffa-Bachi and D. Naor. Chemical approaches to the cell receptor problem. Annals. N.Y. Acad. Sci. 190:432-442, 1971.
14. D. Naor, C. Henry and H. Fudenberg. An in vitro immune response to penicillin. J. Immunol. 107:302-305, 1971.
15. D. Naor and R. Mishell. In vitro immunity to TNP and penicillin. Specific inhibition with hapten-conjugated isologous red cells. J. Immunol. 108:246-252, 1972.
16. D. Naor, S. Morecki and E. Kedar. Differential induction and suppression of direct and indirect PFC responses to TNP conjugated to heterologous erythrocytes. Adv. Exp. Med. Biol. 29:225-232, 1972.22naor/cv-dn.doc
17. D. Sulitzeanu, S. Morecki, D. Naor and R. Tanenbaum. Specific interactions of antigens with cells. In: 3rd International Convocation on Immunology, D. Pressman, T.B. Tomasi, Jr., A.L. Grossberg, N.R. Rose, (eds), pp.354-368, Karger, Basel. 1973.
18. D. Naor, S. Morecki and G.F. Mitchell. Differential induction of anti-trinitrophenyl plaque forming cell responses to lightly and heavily conjugated trinitrophenylated heterologous and autologous erythrocytes in mice. Eur. J. Immunol.4:311-314, 1974.
19. S. Zolla, D. Naor and P. Tanapatchaiyapong. Cellular basis of of immunodepression in mice with plasmacytomas. J. Immunol. 112:2068-2076, 1974.
20. D. Sulitzeanu, S. Morecki and D. Naor. Specific interaction of antigen with cells studied by means of rosette formation. Israel J. Med. Sci. 10:1397-1404, 1974.
21. S. Zolla and D. Naor. Restoration of immune competence in tolerant mice by parabiosis to normal mice. J. Exp. Med. 5:1421-1426, 1974.
22. D. Naor, R. Saltoun and F. Falkenberg. Lack of requirement for thymocytes for efficient antibody formation to trinitrophenylated mouse red cells in mice: role for thymocytes in suppression of the immune response. Eur. J. Immunol. 5:220-223, 1975.
23. S. Zolla, F. Falkenberg and D. Naor. Is tolerance an active or a defective state? Proceedings of the Fifth International Congress of the Transplantation Society, (eds.,M. Schlesinger and R.E. Billingham) Transplant. Proc. 7, Suppl. 1 pp. 381-383, 1975.
24. D. Naor, R. Berman-Goldman, M. Kahan, H. Goldfisher, R. Laskov, E. Simon and R. Tchakirov. Induction of hapten recognizng helper function by heavily trinitrophenylated sheep erythrocytes erythrocytes. Adv. Exp. Med. Biol. 66:253-260,1975.
25. M. Kahan, R. Berman-Goldman, R. Saltoun and D. Naor. Studies on the immune response to fixed antigens. Preferential induction of helper function with heavily trinitrophenylated sheep erythrocytes and glutaraldehyde treated sheep erythrocytes. J. Immunol. 117:16-22, 1976.
26. N. Galili, D. Naor, B. Asjo and G. Klein. Induction of immune responsiveness in genetically low-responsive tumor host combination by chemical modification of the immunogen. Eur. J. Immunol. 6:473-476, 1976.
27. D. Naor and N. Galili. Immune response to chemically modified antigens. Review article. Prog. Allergy 22:107-146, 1977.
28. E. Kedar, E. Unger,N. Galili, G. Klein, B. Asjo, B. Bonavida and D. Naor. Immunogenicity of tumor cells modified by trinitrobenzene sulfonic acid (TNBS). In: Membranes and neoplasia. New approaches and strategies. V.T. Marchesi (ed), pp.109-121, Alan R. Liss, New York, 1976.
29. D. Naor, B. Bonavida, R.A. Robinson, I.N. Shibata, D.E. Percy, D. Chia and E.V. Barnett. Immune response of New Zealand (NZB and NZB/W) mice to trinitrophenylated mouse red cells. Eur. J. Immunol. 6:783-789, 1976.
30. D. Naor, B. Bonavida and R.L. Walford. Autoimmunity and aging: The age-related 33naor/cv-dn.doc response of a long-lived strain to trinitrophenylated syngeneic mouse red blood cells. J. Immunol. 117:2204-2208, 1976.
31. D. Naor and C. O`Toole. Cryopreservation of immunological memory and other lymphoid cell functions. J. Immunol. Methods 16:361-370, 1977.
32. D. Naor and M. Kahan. Studies on the immune response to fixed antigens. II. Optimal conditions for inducing and eliciting helper function by fixed antigens and the mechanism responsible for this effect. Israel J. Med. Sci. 13:561-576, 1977.
33. D. Naor. Immune surveillance against autoimmunity. Review paper. In: Dynamic aspects of host-parasite relationship. V.3. A. Zukerman (ed.), pp. 9-31, Keter, Jerusalem, 1979.
34. R.F. Ashman and D. Naor. Defective receptor capping and regeneration in the antigen binding cells of tolerant mice. In: Immune system: genetics and regulation.
E.E. Sercarz, L. Herzenberg and C.F. Fox (eds.), pp. 707-711, Academic Press, New York, 1977.
35. D. Naor. Delayed type hypersensitivity. Encyclopedia Hebraica. V. 30 pp. 501-504,1978.
36. D. Naor. Suppressor cells: Permitters and promoters of malignancy? Invited review.Adv. Cancer Res. 29:45-125, 1979.
37. B. Leshem and D. Naor. Cellular assay for measuring anti-erythrocyte antibody responses. J. Immunol. Methods 20:263-275,1978.
38. N. Galili, B. Devens, D. Naor, S. Becker and E. Klein. Immune responses to weakly immunogenic virally induced tumors. I. Overcoming low responsiveness by priming
mice with a syngeneic in vitro tumor line or allogeneic cross-reactive tumor. Eur. J. Immunol. 8:17-22, 1978.
39. B. Devens, N. Galili, O. Deutsch, D. Naor and E. Klein. Immune responses to weakly immunogenic virally induced tumors. II. Suppressive effects of the in vivo carried tumor YAC. Eur. J. Immunol. 8:573-578, 1978.
40. B. Leshem and D. Naor. Studies on the immune response to fixed antigens. III. Induction of helper function for antibody dependent cellular cytotoxicity responses. J. Immunol. 121:401-408, 1978.
41. E. Klein, S. Becker, N. Galili, B. Devens and D. Naor. Cell mediated cytotoxic reactions against oncorna virus induced lymphomas in mice. In: Proceedings of Erwin Riesch Symposium on Cytotoxic Cell-Interaction and Immunostimulation. 1979.
42. R.F. Ashman and D. Naor. Membrane defects of the tolerant B cell. I. Failure of antigen-induced capping. Cell. Immunol. 44:314-328, 1979.
43. B. Devens and D. Naor. Immune responses to weakly immunogenic virally induced tumors. III. Genetically unrestricted cytolysis of allogeneic tumor target cells. J.Immunol. 122:1397-1401, 1979.
44. B. Devens, L. Schochat and D. Naor. Immune responses to weakly immunogenic virally induced tumors. V. Short in vitro cultivation of YAC changes its antigenic44naor/cv-dn.doc
properties. Cell. Immunol. 44:442-453, 1979.
45. B. Leshem and D. Naor. Studies on the immune response to fixed antigens. IV.Recall of immunologic memory with fixed antigens. Israel J. Med. Sci. 16:25-32, 1980.
46. B. Devens, D. Naor and E. Kedar. Immune response to weakly immunogenic virally induced tumors. IV. Dissociated recognition of H-2 and tumor-associated antigens.Transplantation 28:389-395, 1979.
47. D. Naor. Unresponsiveness to modified self antigens. A censorship mechanism controlling autoimmunity. Invited review. Immunological Reviews 50:187-226, 1980.
48. B. Devens, N. Galili, D. Naor and E. Klein. Opposing tumorogenic and immunogenic properties of the in vitro and the in vivo sublines of Moloney induced tumor. In: Cell Biology and Immunology of Leukocyte Function. M.R. Quastel (ed.) pp. 707-714.Academic Press, New York, 1979.
49. O. Deutsch, B. Devens and D. Naor. Immune responses to weakly immunogenic murine-leukemia-virus induced tumors. VII. Kinetic studies on various parameters of effects induced with suppressor cells. Isr. J. Med. Sci. 16:530-537, 1980.
50. O. Deutsch, B. Devens and D. Naor. Immune responses to weakly immunogenic murine-leukemia-virus-induced tumors. VIII. Characterization of suppressor cells. Isr. J. Med. Sci. 16:538-544, 1980.
51. B. Devens and D. Naor. Immune responses to weakly immunogenic virally induced tumors. VI. Comparison of the immune response of the hybrid to the immune responses of the parents reveals "hybrid responsiveness" effect. J. Immunol. 125:988-994. 1980.
52. B.Y. Klein, S. Frenkel, A. Ahituv and D. Naor. Immunogenicity of subcellular fractions and molecular species of MuLV-induced tumors. I. Screening of immunogenic components by isopycnic ultracentrifugation and polyacrylamide electrophoresis of a tumor homogenate. J. Immunol. Methods 38:325-341, 1980.
53. B.Y. Klein, B. Devens, O. Deutsch, A. Ahituv, S. Frenkel, B.J. Kobrin and D. Naor. Isolation of immunogenic and suppressogenic determinants of nonimmunogenic YAC tumor and the change in its immunogenic repertoire after in vitro cultivation.Transplant. Proc. 8:790-797, 1981.
54. B.J. Kobrin, D. Naor and B.Y. Klein. Immunogenicity of subcellular fractions and molecular species of MuLV-induced tumors. II. Stimulation of syngeneic anti-tumor cell-mediated immune responses by subcellular fractions and molecular species of the Rauscher-virus-induced RBL5 tumor. J. Immunol. 125:1874-1882, 1981.
55. R. Sharon, B.Y. Klein, Y. Avraham, N. Kaner, N. Tarcic and and D. Naor. The change of immunogenic repertoire of YAC tumor cells after in vitro cultivation. In: Proceedings of the 14th International Leucocyte Conference. Mechanisms of lymphocyte activation. K. Resch and H. Kirchner, (eds.) pp. 636-639. Elsevier/North Holland Biomedical Press, Amsterdam, 1981.
56. B. Devens, O. Deutsch, Y. Avraham and D. Naor. Immune responses to weakly immunogenic virally induced tumors. IX. Mice injected with the in vitro variants of YAC tumor (YAC-1) resist lethal doses of the tumorgenic YAC cells. Immunobiology 55naor/cv-dn.doc 159:432-443, 1981.
57. D. Naor, B.Y. Klein and R. Sharon. T cells and cancer.Proceedings of the XIth Triennial World Congress of Pathology. Advances in Pathology 1:293-298, 1982.
58. D. Naor and N. Tarcic. Control of autoimmune responses induced with modified self antigens. Annals N.Y. Acad. Sci. 392: 178-190, 1982.
59. B.Y. Klein, R. Sharon, N. Tarcic and D. Naor. Induction of antitumor reactive cells or suppressor cells by different molecular species isolated from the same non-immunogenic tumor. Immunobiology 163:7-21, 1982.
60. A. Ahituv, D. Naor, R. Sharon, N. Tarcic and B.Y. Klein.Immunogenicity of subcellular fractions and molecular species of of MuLV-induced tumors. III. Stimulation of syngeneic antitumor responses by subcellular fractions and molecular species of Moloney virus-induced tumors in CBA and A mice. Cancer Immunol. Immunother.14:16-26, 1982.
61. B.Y. Klein, R. Sharon, Y. Avraham, A. Ahituv and D. Naor. Isolation of immunogenic entities from nonimmunogenic transplantable tumors and their normal cell counterparts. Transplant. Proc. 15:225-231, 1983.
62. N. Tarcic and D. Naor. Delayed-type hypersensitivity induced in immunodeficient mice
with syngeneic modified self antigens: A suggestive model of autoimmune response.
Eur. J. Immunol. 12:961-966, 1982.
63. N. Tarcic, R. Sharon, E. Rosenmann and D. Naor. Auto-delayed type hypersensitivity
(DTH) induced in immunodeficient mice with syngeneic modified self antigens. II.
Suppressor T cells control the autoimmune response. Scand. J. Immunol. 19:111-
121, 1984.
64. D. Naor. Coexistence of immunogenic and suppresssogenic epitopes in tumor cells
and various types of macromolecules. Invited editorial review. Cancer Immunol.
Immunother. 16:1-10, 1983.
65. A. Adler, J.A. Stein, E. Kedar, D. Naor and D.W. Weiss. Intralesional injection of IL-2
expanded autologous lymphocytes in melanoma and breast cancer patients. A pilot
study. J. Biol. Resp. Modifiers. 3:491-500, 1984.
66. I. Klein and D. Naor. Self reactive delayed type hyper-sensitivity (DTH) induced in
mice by syngeneic lymphoblasts. Immunobiology. 169:45-59, 1985.
67. N. Tarcic, R. Baler and D. Naor. Auto-delayed-type hypersensitivity (DTH) induced in
immunodeficient mice with modified self antigens. III. Suppressive T cell factor (SF)
controls the autoreactivity against self antigens. Scand. J. Immunol. 20:389-401,
1984.
68. N. Tarcic, B.Y. Klein and D. Naor. Auto-delayed-type hypersensitivity (DTH) induced
in immunodeficient mice with modified self antigens. IV. Characterization of the
suppressive T cell factor (SF) that controls the autoreactivity against self antigens.
Scand. J. Immunol. 20:403-411, 1984.
69. D. Naor and J.S. Duke-Cohan. Suppressor cells and malignancy, I. Suppressor
macrophages and suppressor T cells in experimental animals. Invited review.
6
6naor/cv-dn.doc
Advances in Immunity and Cancer Therapy, Vol. 2. pp 1-129 P.K.Ray (ed.)
Springer-Verlag, New York, 1986.
70. B.Y. Klein, S. Frenkel and D. Naor. Isolated soluble fractions from the murine B16
melanoma induce primary in vitro syngeneic antitumor responses. Cancer Immunol.
Immunother. 18:195-202, 1984.
71. R. Sharon and D. Naor. The isolation of immunogenic molecular entities from
immunogenic and non-immunogenic tumor homogenates by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE). Cancer Immunol. Immunother.
18:203-208, 1984.
72. J.S. Duke-Cohan, H. Weinberg, R. Sharon and D. Naor. Immunological function in
Osteoporosis. Clin. Immunol. Immunopathol. 35:125-129, 1985.
73. D. Naor, B.Y. Klein, N. Tarcic and J.S. Duke-Cohan. Immunosuppression in human
malignancy. Humana Press, New Jersey, 1988.
74. P. Hutchings, D. Naor and A. Cooke. Effects of low doses of cyclophosphamide and
low doses of irradiation on the regulation of induced erythrocyte autoantibodies in
mice. Immunology. 54:97-104, 1985.
75. D. Naor and A. Langer. Analysis of the cyclosporin (CSA) mechanism in
immunological autoreactive model of delayed type hypersensitivity. Transplant. Proc.
17:2706-2708, 1985.
76. D. Naor, N. Tarcic and R. Baler. Control of in vivo immunological autoreactivities with
suppressive T cell factor (TF) derived from hybridoma cell line. Transplant. Proc.
17:2617-2621, 1985.
77. A. Langer, E. Rosenmann and D. Naor. The effect of cyclosporin on murine
autoreactive delayed type hypersensitivity induced with syngeneic lymphoblasts.
Immunopharmacology. 10:147-155, 1985.
78. D. Naor, N. Tarcic, I. Klein, and A. Langer. Immunological autoreactivity to
lymphoblast antigens and its suppression by cyclosporin (CsA) or suppressor T cell
factors (TsFs). UCLA Symposia on Molecular and Cellular Biology, New Series,
Volume 41. Immune Regulation by Characterized Polypeptides. G. Goldstein, J.F.
Bach, H. Wigzell (eds.), Alan R. Liss, Inc., New York, pp. 165-179, 1987.
79. J.S. Duke-Cohan, I. Leichter, N. Husseini, R. Sharon, J.Stessman, D. Naor and H.
Weinberg. Immune function in Osteoporosis: A central role for peripheral blood
monocytes in immune suppression and Osteopaenia. Proc. of the 7th International
Workshop on Calcified Tissue. Ein Gedi, Israel, 1986. Current Advances in
Skeletogenesis. 3:304-310, 1986 .
80. N. Tarcic and D. Naor. The genetic control of syngeneic delayed type hypersensitivity
(syn-DTH). Immunogenetics. 24:31-134, 1986.
81. D. Naor. Suppressor cells and human malignancy. Clin. Immun. Newsletter. 8: 65-
69, 1987.
82. V.E. Kelley, D. Naor, N. Tarcic, C.N. Gaulton, and T.B. Strom. Anti-Interleukein 2
receptor antibody suppresses delayed-type hypersensitivity to foreign and syngeneic
7
7naor/cv-dn.doc
antigens. J. Immunol. 137:2122-2124, 1986.
83. J.S. Duke-Cohan, R. Hirt, A. Dahan, and D. Naor. On the immune reaction to
autologous human lymphoblasts: Evidence for the stimulation by activating factors
rather than induction by autoantigens. Clin. Immunol. Immunopathol. 43:229-242,
1987.
84. I. Klein, B.Y. Klein, and D. Naor. Self-reactive delayed type hypersensitivity induced in
mice by syngeneic lymphoblasts. II. Isolation of two distinct lymphoblast antigens, one
of which reacts (or cross-reacts) with anti-H-2Dd monoclonal antibody. Scand. J.
Immunol. 27: 209-222, 1988.
85. I. Klein, and D. Naor. Self-reactive delayed type hypersensitivity induced in mice by
syngeneic lymphoblasts. III. Immunological characterization of the small and large
antigens of the blast cells. Scand. J. Immunol. 27:385-392, 1988.
86. R. Sharon, H. Giloh, and D. Naor. Experimental autoimmune anemia induced with
haptenated syngeneic mouse red blood cells and low dose X-irradiation. Clin.
Immunol. Immunopathol. 47: 310-322, 1988.
87. D. Naor, N. Tarcic, P. De Berardinis, M. Kahan, and M. Feldmann. Autoreactivity
against class I or class II antigens -- immunological downregulation mechanism? Bull.
Inst. Pasteur, 87:3-17, 1989.
88. J.S. Duke-Cohan, R. Hirt, M. Rottem, A. Ben-Zvi, A. Rubinow, and D. Naor. Use of an
autologous reaction in vitro to assess contributions of T and B lymphocytes to immune
hyperreactivity of atopics. Clin. Exp. Allergy 19, 163-168, 1989.
89. D. Naor, G. Essery, M. Kahan, and M. Feldmann. T-cell clone anti-clone interactions
effects on suppressor and helper activities. J. Autoimmun. 2 (Supp.), 3-14, 1989.
90. R. Sharon and D. Naor. Experimental model of autoimmune hemolytic anemia
induced in mice with Levodopa. Clin. Immunol. Immunopathol., 52, 160-172, 1989.
91. I. Klein and D. Naor. Autoinflammatory response to self-antigens of lymphoblasts.
Isr. J. Med. Sci. 24:373-375, 1988.
92. N. Tarcic, C. S. David and D. Naor. Auto-delayed-type hypersensitivity induced in
immunodeficient mice with modifed self-antigens. V. Cellular autoreactivity directed
against self-H-2Dd subregion mediates the inflammatory responses.Immunology,
67:184-190, 1989.
93. H. Lugasi, S. Hajos, J. R. Murphy, T. B. Strom, J. Nichols, C. Penarroja and D. Naor.
Murine spontaneous T cell leukemia constitutively expressing IL-2 receptor-a model
for human T cell malignancies expressing IL-2 receptor. Int. J. Cancer, 45:163-167,
1990.
94. J. S. Duke-Cohan, A. Rubinow, R. Hirt and D. Naor. The reaction against autologous
lymphoblasts as an indicator of lymphocyte hyperreactivity in rheumatoid arthritis.
Clin. Immunol. Immunopathol., 54:298-308, 1990.
95. E. Alvarez, C. Mongini, C.I. Waldner, T.B. Fenandez, D. Naor and S.E. Hajos. The
inter-relationships between spontaneous murine T cell leukemia LB and the immune
system: LB is a nonimmunogenic tumor in its syngeneic host. J. Exp. Clin. Cancer
8
8naor/cv-dn.doc
Res. 8, 181-191, 1989.
96. D. Naor, G. Essery, N. Tarcic, M. Kahan and M. Feldmann. Interactions between
autologous T cell clones. Cell Immunol. 128:490-502, 1990.
97. D. Naor, G. Essery, N. Tarcic, M. Kahan, J.R. Lamb and M. Feldmann. Specific
interactions between a human CD4+ clone and autologous CD4+ bifunctional
immunoregulatory clones. Immunol. Rev. 116, 63-83, 1990.
98. M.A. Zahalka and D. Naor. Inflammatory Response induced with an isolated
syngeneic activation antigen shared by normal lymphoblasts and YAC lymphoma
cells. Clin. Immunol. Immunopathol. 59:72-88, 199l.
99. Naor, D. Essery, G. Tarcic, N. Kahan, M. and Feldmann, M. Regulatory interactions
among autologous T cell clones human bifunctional T cell clones regulate the activity
of an autologous T cell clone. Ann. N. Y. Academy of Sciences. 636, 135-146, 199l.
100. Naor, D. Short analytical review. A different outlook at the phenotype-function
relationships of T cell Subpopulations. Fundamental and clinical implications. Clin
Immunol. Immunopathol. 62, 127-132, 1991.
101. Pillemer, G., Lugasi-Evgi, H., Scharovsky, G., and Naor, D. Insulin dependence of
murine lymphoid T cell leukemia. Int. J. Cancer. 50, 80-85, l992.
102. Sharon, R. and Naor, D. Experimental model of autoimmune hemolytic anemia
induced in mice with levodopa by intraperitoneal injection or oral feeding. Int. J.
Immunopharmac. 14, 1241-1247, 1992.
103. Naor, D. Bifunctional T cell clones challenge the traditional compartmentalization
concept of the immune system. Arch. Immunol. Ther. Exp. 40, 67-70, 1992.
104. Sharon, R., Pillemer, G., Ish-Shalom, D., Kalman, R., Ziv, E., Berry, M.E. and Naor,
D. Insulin dependence of murine T-cell lymphoma II. Insulin deficient diabetic mice
develop resistance to the lymphoma growth. Int. J. Cancer., 53, 843-849, 1993.
105. Sharon, R. Polliack, A., Rahamim, E., Kahane, A. and Naor, D. Autoimmune
hemolytic anemia induced with levadopa or -methyldopa animal model and clinical
implications. Advances in Allergy and Immunology. 2, 65-78, 1993.
106. Zahalka, M.A. Okon, E. and Naor, D. Blocking lymphoma invasiveness with
monoclonal antibody directed against the ß chain of the leukocyte adhesion molecule
(CD18). J. Immunol. 150, 4466-4477, 1993.
107. Zahalka, M.A. and Naor, D. ß2-Integrin dependent aggregate formation between
LB T cell lymphoma and spleen cells: assessment of correlation with spleen
invasiveness. International Immunol. 6, 917-924, 1994.
108. Ish-Shalom, D., Tzivion, G., Cristoffersen, C.T., Urso, B., De Meyts, P. and Naor,
D., Mitogenic potential of insulin and lymphoma cells lacking IGF-I receptor. Ann.
N.Y. Acad. Sci. 776, 409-415.
109. Stock, R. and Naor, D. Induction of an autoimmune response against syngeneic
lymphoma cells by immunogenic 64-kDa protein isolated from normal balst cells of
BALB/c mice. Cancer Immunol. Immunother. 40, 48-56, 1995.
9
9naor/cv-dn.doc
110. Zahalka, M.A., Okon, E., Gosslar, U., Holzmann, B. and Naor, D. Lymph node (but
not spleen) invasion by murine lymphoma is both CD44 and Hyaluronate-dependent.
J. Immunol. 154, 5345-5355, 1995.
111. Naor, D., Vogt Sionov, R., and Ish-Shalom, D. CD44: Structure, function and its
association with the malignant process. Adv. Cancer Res., 71, 241-319, 1997
112. Naor, D. CD44. Encyclopedia of Immunology. Academic Press, London. 487-491,
1998.
113. Gosslar, U., Jonas, P., Luz, A., Lifka, A., Naor, D., Hamann, A., and Holzmann, B.
Predominant role of (4-integrins for distinct steps of lymphoma metastasis. Proc. Natl.
Acad. Sci. USA vol. 93, 4821-4826, 1996.
114. Rocha, M., Kruger, A. Umansky, V., von Hoegen, P., Naor, D., and Schirrmacher,
V. Dynamic expression changes in vivo of adhesion and costimulatory molecules
determine load and pattern of lymphoma liver metastasis. Clin. Cancer Res. 2, 811-
820, 1996.
115. Naor, D., Vogt Sionov, R., Zahalka, M., Kantor, B., Rochman, M., Holzmann, B. and
Ish-Shalom, D. Organ-specific requirements for cell adhesion molecules during
lymphoma cell dissemination. Curr. Top. Microbiol. Immunol. 231, 143-166, 1998
116. Ish-Shalom, D., Christoffersen, C.T., Vorwerk, P., Sacerdoti-Sierra, N., Shymko,
R.M., Naor, D. and De Meyts, P. Mitogenic properties of insulin and insulin analogues
mediated by the insulin receptor. Diabetologia. 40, S25-S31, 1997
117. Vogt Sionov, R. and Naor, D. Hyaluronan-independent lodgement of CD44+
lymphoma cells in lymphoid organs. Int. J. Cancer. 71, 462-469, 1997.
118. Vogt Sionov, R. and Naor, D. Calcium-and calmodulin-dependent PMA-activation of
CD44 adhesion molecule. Cell Adhesion and Communication. 6: 503-523, 1998.
119. Rochman, M., Moll, J., Herrlich, P., Wallach, S.B., Nedvetzki, S., Vogt Sionov, R.,
Golan, I., Ish-Shalom, D., and Naor, D. The CD44 receptor of lymphoma cells:
structure-function relationships and mechanism of action. Cell Adhesion and
Communication. 7, 331-347, 2000.
120. Nedvetzki, S., Walmsley, M., Alpert, E., Williams, R.O., Feldmann, M. and Naor, D.
CD44 involvement in experiment collagen-induced arthritis (CIA). J. Autoimmunity.
13, 39-47, 1999.
121. Wallach, S B.., Friedmann, A., and Naor, D. The CD44 receptor of the mouse LB T
cell lymphoma: Analysis of the isoform repertoire and ligand binding properties by
reverse-transcriptase polymerase chain reaction (RT-PCR) and anti-sense
oligonucleotides. Cancer Detection and Prevention. 24, 33-45, 2000.
122. Weiss, L., Slavin, S., Reich, S., Cohen, P., Shuster, S., Stern, R., Kaganovsky, E.,
Okon, E., Rubinstein, A.M., and Naor, D. Induction of resistance to diabetes in non-
obese diabetic mice by targeting CD44 with specific monoclonal antibody. Proc. Natl.
Acad. Sci. USA. 97, 285-290, 2000.
123. Naor, D. CD44. Encyclopedia of Molecular Medicine. John Wiley & Sons. Invited
10
10naor/cv-dn.doc
entry. 2000.
124. Naor, D., Nedvetzki, S., Golan, I. and Faitelson, Y. CD44 in Cancer. Critical
Reviews in Clinical Laboratory Sciences. 39, 527-579, 2002
125. Wallach-Dayan, S. B., Grabovsky, V., Moll, J., Sleeman, J., Herrlich, P., Alon, R.
and Naor, D. CD44-dependent lymphoma cell dissemination: a cell surface CD44
variant, rather than standard CD44, supports in vitro lymphoma cell rolling on
hyaluronic acid substrate and its in vivo accumulation in the peripheral lymph nodes.
Journal of Cell Science. 114, 3463-3477, 2001
126. Naor, D. and Nedvetzki, S. CD44 in Rheumatoid Arthritis. Arthritis Research &
Therapy. 5, 105-115, 2003.
127. Guy, R., Yefenof, E, Naor D., Dorogin, A. and Zilberman, Y. CD44 co-stimulates
apoptosis in thymic lymphomas and T cell hybridomas. Cell. Immunol. 216, 82-92,
2002.
128. Melnik, L., Rochman, M., Ronen, D., Zick, Y. Naor, D., and Golan, I. Identification
of Novel CD44 Ligands May Provide New Targets for Therapy. In: Proceedings of the
2 nd International Conference on Tumor Microenvironment Progression, Therapy &
Prevention, Isaac P. Witz (ed.),pp. 213-220, Monduzzi Editore, Bologna, Italy, 2002.
129. Urso, B., Ilondo, M. M., Holst, P.A., Christoffersen, C.T., Ouwnes., M.,
Giorgetti, S. Van, Obberghen, E., Naor, D., Tornqvist, H., and De Meyts, P. IRS-4
mediated mitrogenic signalling by insulin and growth harmone in LB cells, a murine T-
cell lymphoma devoid of IGF-I receptors. Cellular Signalling. 5630, 1-10, 2002.
130. Nedvetzki, S., Golan, I., Assayag, N., Gonen, E., Caspi, D., Gladnikoff M.Yayon,A.,
and Naor, D. A mutation in a CD44 variant of inflammatory cells enhances the mitogenic
interaction of FGF with its receptor. J. Clin. Invest. 111, 1211-1220, 2003.
131. Avigdor, A., Goichberg, P., Shivtiel, S., Dar, A., Peled, A., Samira, S., Kollet, O.,
Hershkoviz, R., Alon, R., Hardan, I., Ben-Hur, H., Naor, D., Nagler, A., and Lapidot, T.
CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+
stem/progenitor cells to the bone marrow. Blood. 103,2981-2989,2004.
132. Nedvetzki,S.,Gonen, E.,Assayag,N.,Reich, R,,Williams, R.O.,Thurmond,R.L.,Huang,J-
F.,Neudecker,B.A.,F.,Wang,F-S.,Turley,E.A. and Naor,D. RHAMM,a receptor for
hyaluronan-mediated motility compensates for CD44 in inflamed CD44-knockout mice: a
different interpretation of redundancy. PNAS 101,18081-18086,2004.
133. Naor,D and Assayag N. The lesson to be learned from CD44 knockout mice.In
Hyaluronan 2003. Proceedings(eds:Balazs,E.A.and Hascall V.C). Matrix Biology Institute
2004.
134. Tolg,C., Hamilton,S.R, Naor,D., McCarthy,J.B. and Turley,E.A. Analysis of convergent
divergent signaling pathways regulated by Rhamm and CD44: Identification of Actin
Cytoskeleton proteins AS Rhamm binding partners. In Hyaluronan 2003.
Proceedings(eds:Balazs,E.A.and Hascall V.C). Matrix Biology Institute,2004.
135. Naor,D., Nedvetzki,S., Assayag,N., Thurmond,R.L.,Huang J-F.and E.A.Turley. The
mechanism of molecular redundancy in autoimmune inflamation in the context of CD44
deficiency. Ann.N.Y.Acad.Sci.1050,52-63,2005
11
11naor/cv-dn.doc
136. Golan I , Nedvetzki S , Golan I , Eshkar-Sebban L , Levartovsky D , Elkayam O , Caspi D ,
Aamar S , Amital H , Rubinow A , Naor D . Expression of extra trinucleotide in CD44 variant
of rheumatoid arthritis patients allows generation of disease-specific monoclonal antibody.
J Autoimmun. 28: 99-113, 2007.
137. Garin T , Rubinstein A , Grigoriadis N , Nedvetzki S , Abramsky O , Mizrachi-Koll R , Hand
C , Naor D , Karussis D . CD44 variant DNA vaccination with virtual lymph node ameliorates
experimental autoimmune encephalomyelitis through the induction of apoptosis. J Neurol
Sci. 258:17-26, 2007.
138. Lora Eshkar Sebban, Denise Ronen, David Levartovsky, Ori Elkayam, Dan Caspi ,
Suhail Aamar, Howard Amital, Alan Rubinow, Ira Golan, David Naor, Yehiel Zick and
Itshak Golan. The Involvement of CD44 and its Novel Ligand Galectin-8 in Apoptotic
Regulation of Autoimmune Inflammation. J Immunol. 179:1225-1235, 2007.
139. David Naor, Shlomo Nedvetzki, Marita Walmsley, Avner Yayon, Eva A. Turley, Ira
Golan, Dan Caspi, Lora Eshkar Sebban, Yehiel Zick, Tali Garin, Dimitrios Karussis,
Nathalie Assayag-Asherie, Itamar Raz, Lola Weiss, Shimon Slavin and Itshak Golan.
CD44 involvement in autoimmune inflammations: The lesson to be learned from CD44-
targeting by antibody or from knock out mice. Ann NY Acad Sci. 1110:233-47, 2007.
140. Naor D, Wallach-Dayan SB, Zahalka MA, Sionov RV. Involvement of CD44, a molecule
with a thousand faces, in cancer dissemination. Semin Cancer Biol.18:260-267,2008.
141. Weiss L, Botero-Anug AM, Hand C, Slavin S, Naor D. CD44 gene vaccination for
insulin-dependent diabetes mellitus in non-obese diabetic mice. Isr Med Assoc J.10:20-
5,2008
142 . Gonen E, Nedvetzki S, Naor D, Shpigel NY. CD44 is highly expressed on milk
neutrophils in bovine mastitis and plays a role in their adhesion to matrix and mammary
epithelium. Vet Res. 2008 39:29,2008.
143. Shulamit Batya Wallach-Dayan, Ariel M. Rubinstein, Carla Hand, Raphael Breuer
and David Naor DNA Vaccination with CD44 Variant Isoform Reduce Mammary Tumor
Local Growth and Lung Metastasis. Molecular Cancer Therapeutic (MCT). 7:1615-1623 ,
2008.
144. Vagima Y , Avigdor A , Goichberg P , Shivtiel S , Tesio M , Kalinkovich A , Golan K , Dar
A , Kollet O , Petit I , Perl O , Rosenthal E , Resnick I , Hardan I , Gellman YN , Naor D ,
Nagler A , Lapidot T .MT1-MMP and RECK are involved in human CD34+ progenitor
cell retention, egress, and mobilization. J Clin Invest. 119:492-503, 2009.
145. Kahaly GJ, Shimony O, Gellman YN, Lytton SD, Eshkar-Sebban L,Rosenblum N,
Refaeli E, Kassem S, Ilany J, and Naor D Regulatory T-cell in Graves’ orbitopathy:
Baseline findings and immunomodulation by anti-T lymphocyte globulin. J Clin Endocrinol
Met (JCEM). 96: 422-429,2011.
146. Turley EA, and Naor D. RHAMM and CD44 peptides-analytic tools and potential drugs
2011. Front Biosci. 17:1775-1794, 2012.
147. Shimony O,Nagler A,Gellman YN, Refaeli E, Rosenblum N. Eshkar-Sebban L
Yerushalmi R, Shimoni A, Lytton SD, Stanevsky A,Or R, Naor D. Anti-T lymphocyte
12
12naor/cv-dn.doc
globulin (ATG) induces generation of Regulatory T Cells, at least part of them
express
activated CD44. J Clin Immunol 32:173–188 , 2012
148. Girbl T , Hinterseer E , Grössinger EM , Asslaber D , Oberascher K , Weiss L , Hauser-
Kronberger C , Neureiter D , Kerschbaum H , Naor D , Alon R , Greil R , Hartmann TN .
CD40- mediated activation of chronic lymphocytic leukemia cells promotes their CD44-
dependent adhesion to hyaluronan and restricts CCL21 induced motility. Cancer Res.
73(2):561-570, 2013
149. Benjamin Gesundheit MD PhD 1 , Joshua Rosenzweig MD 1 , David Naor PhD 2 ,
Armand Keating MD 3 , Bernard Lerer MD 4 , Dizah Zachor MD 5 , Vaclav Procházka MD
PhD 6 , Michal Melamed PhD 1 , Donald A. Kristt MD 5 , Abraham Steinberg MD 8 , Cory
Shulman PhD 9 , Paul Hwang MD 10 , Gideon Koren MD 11 , Asnat Walfish MD 12 , Vijendra
Singh PhD 13 , Basan Gowda S Kurkalli PhD 14 , Jacob R Passweg MD 15 , John Snowden
MD 16 , Ryad Tamouza MD PhD 17 , Marion Leboyer MD PhD 18 , Dominique Farge-Bancel
MD 19 , Paul Ashwood PhD 20 . Autoimmunity and Autism Spectrum Disorders. J
Autoimmun. 2013 44:1-7, 2013
150. Gesundheit B, Ashwood P, Keating A, Naor D, Melamed M, Rosenzweig J
Therapeutic properties of mesenchymal stem cells for autism spectrum disorders. Med
Hypotheses. 2015 Mar;84(3):169-77.
151. Nathalie Assayag-Asherie, Dror Sever, Marika Bogdani, Pamela Johnson, Talya
Weiss, Ariel Ginzberg, Sharon Perles, Lola Weiss, Lora Eshkar Sebban, Eva A. Turley,
Elimelech Okon, Itamar Raz, and David Naor. Can CD44 be a mediator of cell
destruction ? the challenge of type 1 diabetes . PLoS One. 2015; 10(12): e0143589
152. David Naor .Editorial: Interaction between hyaluronic acid and its receptors
(CD44,RHAMM) regulates the activity of inflammation and cancer . Front. Immunol.
7:39.doi: 10.3389/fimmu.2016.00039
153. Barzilay R, Ventorp F, Segal-Gavish H, Aharony I, Bieber A, Dar S, Vescan M,
Globus R, Weizman A, Naor D, Lipton J, Janelidze S, Brundin L, Offen D.CD44
Deficiency Is Associated with Increased Susceptibility to Stress-Induced Anxiety-like
Behavior in Mice. J Mol Neurosci. 2016 Sep 13.
154. Pinner E, Gruper Y, Ben Zimra M, Kristt D, Laudon M, Naor D, Zisapel N CD44
Splice Variants as Potential Players in Alzheimer's Disease Pathology. J Alzheimers Dis.
58(4):1137-1149. 2017
155. Beider K, Naor D, Voevoda V, Ostrovsky O, Bitner H, Rosenberg E, Varda-Bloom
N, Canaani J, Danilesko I, Shimoni A, and Nagler A., Dissecting the mechanisms
involved in anti-human T-lymphocyteimmunoglobulin (ATG)-induced tolerance in the
setting of allogeneic stem cell transplantation - potential implications for Graft versus
Host Disease. Oncotarget, 8(53):90748-90765, 2017
156. Toshiyuki Murai, Hiroto Kawashima and David Naor. Editorial: Cell-Cell and Cell-
Matrix Adhesion in Immunobiology and Cancer. Front. Immunol. 10:3126. doi:
10.3389/fimmu.2019.03126
13
13naor/cv-dn.doc
157. D. Naor, M. Hemed-Shaked, M. Cowman, J Kim, J. Armengol, J. Alemany,
D.Kanduc, A human-derived 5-mer peptide (MTADV), which restrictively alleviates the pro-
inflammatory activity of serum amyloid a (SAA), substantially ameliorates IBD pathology: new
potential drug (MTADV) and therapeutic target candidate (SAA) for IBD. Inflamm. Bowel Dis.
6:S3–4 (2020)
158. Maayan Hemed-Shaked , Mary K Cowman , Jin Ryoun Kim , Xiayun Huang , Edward
Chau, Haim Ovadia, Keren-Or Amar , Lora Eshkar-Sebban , Michal Melamed , Libat Bar
Lev , Eli Kedar , Jordi Armengol , Jorge Alemany , Shaul Beyth, Eli Okon, Darja Kanduc,
Sharona Elgavish , Shulamit B Wallach-Dayan , Shmuel Jaffe Cohen , David Naor
MTADV 5-MER peptide suppresses chronic inflammations as well as autoimmune
pathologies and unveils a new potential target-Serum Amyloid A . J Autoimmun . 2021 Nov;
124:102713
159. David Naor, Mary Cowman, Jin Kim, Maayan Hemed-Shaked . MTADV 5-MER
PEPTIDE SUPPRESSES IBD PATHOLOGY AND UNVEILS A NEW POTENTIAL TARGET-
SERUM AMYLOID A. Gastroenterology Vol. 162, No. 3S.